Septerna (SEPN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jul, 2026Opening remarks and agenda
The meeting was called to order by the CFO, who also served as chairman and secretary, with the chief legal officer taking minutes.
The meeting was held virtually to facilitate broader stockholder participation.
The agenda included formal business as described in the proxy statement, with questions limited to official business.
Board and executive committee updates
Current board members and executive officers were introduced, including the CEO, President/COO, CFO, and other key leaders.
Corporate governance
Ernst & Young LLP was present as the independent registered public accounting firm, and an Inspector of Election was appointed.
Only validated stockholders could vote and ask questions via the virtual platform.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Septerna
- Advancing oral therapies for endocrine and immunological diseases via innovative GPCR targeting.SEPN
44th Annual J.P. Morgan Healthcare Conference9 Jul 2026 - Rapid GPCR drug discovery platform advances oral therapies with key data expected in 2025.SEPN
43rd Annual J.P. Morgan Healthcare Conference 20258 Jul 2026 - Lead GPCR-targeting drugs advance in trials, leveraging a novel discovery platform.SEPN
Bank of America Global Healthcare Conference 202613 May 2026 - Revenue surged to $26.5M, net loss narrowed, and cash runway is secured into 2029.SEPN
Q1 202611 May 2026 - Virtual annual meeting to vote on director elections and auditor ratification.SEPN
Proxy filing30 Apr 2026 - Proxy covers director elections, auditor ratification, compensation, and governance policies.SEPN
Proxy filing30 Apr 2026 - SEP-631 advances to phase II for urticaria after strong phase I data; SEP-479 nears phase I start.SEPN
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - Rapidly advancing oral GPCR therapies with strong pipeline and Novo Nordisk partnership.SEPN
Corporate presentation16 Mar 2026 - Pipeline advances and improved financials set stage for clinical milestones in 2026.SEPN
Q4 20259 Mar 2026